Healthcare investing has become a rollercoaster, with the sector swaying between progress in medical advancements and hurdles like clinical trial results and economic factors. Industry titans such as Eli Lilly and Novo Nordisk have faced significant setbacks, and now Jim Cramer is drawing attention to CVS Health, seeing potential in this lesser-mentioned competitor. The healthcare landscape’s fluctuations have set the stage for CVS’s market dynamics, with recent developments pushing it into the spotlight.
Jim Cramer has oscillated between healthcare stocks, offering mixed reactions based on performance. While Eli Lilly and Novo Nordisk were previously the favorites due to substantial growth, current conditions have led Cramer to reconsider as their past performance stagnates. In contrast, CVS Health, having faced profit challenges within its Aetna insurance branch, is showing signs of recovery. Its stock performance, notably rising by almost 70% this year, is among the most noteworthy developments in the market, drawing Cramer’s interest when he previously favored other stocks.
What Anchors Cramer’s Confidence in CVS?
Jim Cramer expresses a newfound optimism for CVS Health, perceiving a turning point despite the stock being 33% lower than its peak in 2015. Highlighting CVS’s robust year-to-date performance, Cramer focuses on CVS outpacing its dwindling competition. He underscored the company’s strengthened position following robust earnings and mentioned rivals Walgreens and Rite Aid facing significant challenges. CVS has leveraged these conditions to become dominant in numerous markets.
“CVS has become the last man standing in the retail pharmacy space as its last major rival, Walgreens, is set to be taken private,” Cramer explained.
Why Does Cramer Consider CVS Stock ‘Cheap’?
In discussions about CVS’s valuation, Cramer classifies the stock as undervalued. Trading at approximately 11 times future earnings with a yield of 3.59%, he emphasizes the appealing financial prospects for investors. By addressing issues within the Aetna insurance arm, CVS is channeling resources more effectively into its thriving sectors, further bolstering its market position.
“Problem came from Aetna… prices were too low in a world of higher medical costs,” Cramer noted, reflecting on CVS’s strategic redirection.
The healthcare benefits division within CVS showcases a significant upswing. Improved earnings in this sector coincide with a strategic pivot to focus on areas like Medicare Advantage, leaving less profitable initiatives behind. The market’s response has seen a positive trajectory in its stock price, and forecasts for 2025 suggest further revenues and efficiencies.
While CVS still manages substantial debts, its steady revenue growth and operational refinements present a favorable outlook. Expected interest rate cuts also promise to alleviate financial burdens, enhancing the possibility of stock price appreciation. With analysts projecting strong price targets for CVS shares, the company could see notable gains if ongoing strategies continue yielding results.
Jim Cramer’s prediction that CVS Health is poised for further ascent rests on a foundation of restructuring, competitive edge, and strategic resource allocation. Investors contemplating CVS Health should weigh its performance against broader market conditions and individual financial goals. With projected growth and a history of adapting to market changes, CVS Health appears to offer promising potential.
